Q J Med 1999; 92: 219-222
© 1999 Association of Physicians
Cholesterol in peripheral vascular disease—a suitable case for treatment?
From the Department of Cardiology, Western Infirmary, Glasgow and 1Directorate of General and ENT Surgery, Gartnaval General Hospital, Glasgow, UK
Received 22 October 1998 and in revised form 3 February 1999
Dr A.L. Clark, Department of Cardiology, Western Infirmary, Dumbarton Road, Glasgow G11 6NT. e-mail: ALClark1{at}compuserve.com
We assessed the prevalence of conventional risk factors for ischaemic heart disease in patients with peripheral vascular disease, and the scope for preventative treatment with lipid-lowering therapy in this group, by retrospectively reviewing 299 patients who had undergone peripheral angiography in 1996. A total of 278 patients had severe peripheral vascular disease; 44% were current smokers at the time of their angiogram, and 36% had a history of coronary artery disease (either myocardial infarction, coronary artery bypass surgery, coronary angioplasty or angina). Cholesterol had been measured in 80 (27%) patients, of whom 26 (9%) were receiving treatment for hypercholesterolaemia. Patients with a history of ischaemic heart disease were more likely to have had their cholesterol measured (50% vs. 15%; p<0.001). Hypertension (defined as systolic >160 mmHg or diastolic >90 mmHg) was present in 44%. There was no difference in the distribution of risk factors between those with and those without known ischaemic heart disease. There is a high prevalence of modifiable risk factors for coronary disease in patients with severe peripheral vascular disease. Effective prevention is available for coronary artery disease, but we found low levels of treatment. There is considerable scope for intervention to reduce the risk of coronary disease in such patients.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. G. Federman, D. C. Ranani, R. S. Kirsner, and D. M. Bravata Lipid-Lowering Therapy in Patients With Peripheral Arterial Disease: Are Guidelines Being Met? Mayo Clin. Proc., April 1, 2005; 80(4): 494 - 498. [Abstract] [PDF]
|
|
|
|
 |
|
 J. J. Belch and M. A Creager A focus on risk factor management Vascular Medicine, August 1, 2004; 9(3): 169 - 170. [PDF]
|
|
|
|
 |
|
 M. M. McDermott, A. L. Mandapat, A. Moates, M. Albay, E. Chiou, L. Celic, and P. Greenland Knowledge and Attitudes Regarding Cardiovascular Disease Risk and Prevention in Patients With Coronary or Peripheral Arterial Disease Arch Intern Med, October 13, 2003; 163(18): 2157 - 2162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Y. Liu, A. K. Death, and D. J. Handelsman Androgens and Cardiovascular Disease Endocr. Rev., June 1, 2003; 24(3): 313 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T Hirsch and A. M Gotto Jr Undertreatment of dyslipidemia in peripheral arterial disease and other high-risk populations: an opportunity for cardiovascular disease reduction Vascular Medicine, November 1, 2002; 7(4): 323 - 331. [Abstract] [PDF]
|
|
|
|
 |
|
 W. R. Hiatt Medical Treatment of Peripheral Arterial Disease and Claudication N. Engl. J. Med., May 24, 2001; 344(21): 1608 - 1621. [Full Text] [PDF]
|
|